hVIVO (LON:HVO) Share Price Passes Above 50-Day Moving Average - Time to Sell?

hVIVO plc (LON:HVO - Get Free Report) shares crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 15.76 ($0.21) and traded as high as GBX 17 ($0.23). hVIVO shares last traded at GBX 16.61 ($0.22), with a volume of 1,644,675 shares traded.

Wall Street Analyst Weigh In

Separately, Shore Capital restated a "buy" rating on shares of hVIVO in a report on Thursday, April 10th.

hVIVO Trading Up 2.9 %

The stock has a market capitalization of £127.37 million, a PE ratio of 7.42 and a beta of 0.97. The company's 50 day moving average price is GBX 15.76 and its two-hundred day moving average price is GBX 19.86. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO (LON:HVO - Get Free Report) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, analysts expect that hVIVO plc will post 1.5492958 earnings per share for the current year.

Insider Buying and Selling at hVIVO

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($698,205.23). 14.03% of the stock is owned by company insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.